Cyanotech Corp

Aloha from Kona, Hawaii. Thank you all for joining us today to report Cyanotech's first quarter fiscal year 2023 earnings results. I am Matt Custer, President and Chief Executive Officer of Cyanotech. Joining me on the call today is Felicia Layden, our Chief Financial Officer. I will turn the call over to Felicia to provide our forward-looking statement.

Thanks, Matt. Our discussion today may include forward-looking statements. We do not undertake any obligation to update forward-looking statements either as a result of new information, future events, or otherwise. Our actual results may differ materially from what is described in these forward-looking statements. Some of the factors that may cause results to differ are listed in our publicly filed documents. For additional information, we encourage you to review our 10Q and fiscal year 2022 10K report filed with the Securities and Exchange Commission. I will turn it back to Matt for comments on the quarter. Matt?

The disappointing results in the first quarter were driven primarily by the $2.2 million decrease in sales and a higher cost per kilo of astaxanthin. Lower sales in the quarter for Nutrex of 1.7 million related to timing of shipments to a Nutrex customer as we transitioned to their selling platform in the prior year, offset by sales to key existing customers. There was also a decrease in bulk Spirulina sales of 490,000 due to lower demand by our top customer coupled with timing of orders for other customers. The increase in costs for astaxanthin was driven primarily by lower production in the first quarter due to staff shortages. Production levels normalized late in the first quarter. Turning over to Felicia to discuss the financial results. Felicia?